Novartis AG’s NOVN.S medication has been authorised by the US Food and Drug Administration for the treatment of patients with a kind of advanced prostate cancer that has spread to other regions of the body, the pharmaceutical announced on Wednesday.
Novartis’ Pluvicto is a targeted radioligand therapy for adult patients who have already received anticancer treatment.
The treatment was purchased as part of the company’s $2.1 billion purchase of cancer pharmaceutical Endocyte in 2018.
According to Novartis, Pluvicto is a precision medicine that combines a targeted chemical, or ligand, with a cancer-killing radioactive particle.
Pluvicto has been filed for marketing permission to the European Medicines Agency and other health authorities, according to the business.
According to Novartis, two late-stage trials investigating Pluvicto in early lines of therapy for metastatic prostate cancer are now underway.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…